Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Melanoma treatment is being revolutionized by the development of effective immunotherapeutic approaches. These strategies include blockade of immune-inhibitory receptors on activated T cells; for example, using monoclonal antibodies against CTLA-4, PD-1, and PD-L1 (refs 3-5). However, only a subset of patients responds to these treatments, and data suggest that therapeutic benefit is preferentially achieved in patients with a pre-existing T-cell response against their tumour, as evidenced by a baseline CD8(+) T-cell infiltration within the tumour microenvironment. Understanding the molecular mechanisms that underlie the presence or absence of a spontaneous anti-tumour T-cell response in subsets of cases, therefore, should enable the development of therapeutic solutions for patients lacking a T-cell infiltrate. Here we identify a melanoma-cell-intrinsic oncogenic pathway that contributes to a lack of T-cell infiltration in melanoma. Molecular analysis of human metastatic melanoma samples revealed a correlation between activation of the WNT/β-catenin signalling pathway and absence of a T-cell gene expression signature. Using autochthonous mouse melanoma models we identified the mechanism by which tumour-intrinsic active β-catenin signalling results in T-cell exclusion and resistance to anti-PD-L1/anti-CTLA-4 monoclonal antibody therapy. Specific oncogenic signals, therefore, can mediate cancer immune evasion and resistance to immunotherapies, pointing to new candidate targets for immune potentiation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Tumor-intrinsic activation of the Wnt/β-catenin pathway (15) and deletion or mutation of Pten (16) have been shown to lead to deficient T cell infiltration into the tumor microenvironment and resistance to checkpoint blockade immunotherapy.”
From The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients (2018) · cites this paper as [15]
In the citing paper
“We reveal that the APOE variants exert cell-intrinsic effects on melanoma that impact primary tumor growth and metastatic capacity in a BrafV600E-driven GEMM, a model that has provided numerous important insights into melanoma biology (12,38–40).”
From Apolipoprotein E2 Stimulates Protein Synthesis and Promotes Melanoma Progression and Metastasis (2023) · cites this paper as [12]
In the citing paper
“Combinatorial biomarker strategies that capture attributes of the host and tumor-immune ecosystem will be essential (Fig. 2; refs.121-124).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [123]
In the citing paper
“For example, tumor cell-intrinsic WNT/β-catenin activation has been shown to lead to exclusion of T cells within the TME (123, 155, 156).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [123]
In the citing paper
“Mechanistic studies revealed that Wnt-induced decrease in the expression of the chemokine CCL4 hindered the recruitment of CD103+ DCs and T cells to the tumor microenvironment (Spranger et al., 2015).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Spranger et al., 2015
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Analyzing real-time PCR data by the comparative CT method
Schmittgen, T. D., & Livak, K. J. (2008) · Nature Protocols · doi:10.1038/nprot.2008.73 · Cited by 26,190
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,621
An integrated map of genetic variation from 1,092 human genomes
The 1000 Genomes Project Consortium (2012) · Nature · doi:10.1038/nature11632 · Cited by 7,711
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking
Wilkerson, M. D., & Hayes, D. N. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq170 · Cited by 5,669
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Cited by
Items 501–600 of 1,015
Tubular Dickkopf-3 promotes the development of renal atrophy and fibrosis
Federico, G., Meister, M., Mathow, D., Heine, G. H., Moldenhauer, G., Popovic, Z. V., Nordström, V., Kopp-Schneider, A., Hielscher, T., Nelson, P. J., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.84916 · Cited by 127
DUX4 Suppresses MHC Class I to Promote Cancer Immune Evasion and Resistance to Checkpoint Blockade
Chew, G.-L., Campbell, A. E., De Neef, E., Sutliff, N. A., Shadle, S. C., Tapscott, S. J., & Bradley, R. K. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.06.011 · Cited by 123
“For example, activation of b-catenin signaling promotes T cell exclusion from themelanomamicroenvironment (Spranger et al., 2015), while depletion of LSD1 promotes anti-tumor immune activity (Sheng et al., 2018).”
BackgroundPD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?
Khasraw, M., Reardon, D. A., Weller, M., & Sampson, J. H. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1135 · Cited by 143
Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma
Jerby-Arnon, L., Neftel, C., Shore, M. E., Weisman, H. R., Mathewson, N. D., McBride, M. J., Haas, B., Izar, B., Volorio, A., Boulay, G., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01212-6 · Cited by 127
Zeng, Q., Klein, C., Caruso, S., Maille, P., Laleh, N. G., Sommacale, D., Laurent, A., Amaddeo, G., Gentien, D., Rapinat, A., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.01.018 · Cited by 118
Huber, A., Dammeijer, F. F., Aerts, J. G. J. V., & Vroman, H. H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02804 · Cited by 132
“Some tumors are even able to hamper the recruitment of cDC1s, by downregulating CCL4 signaling upon constitutively active β-catenin signaling and thereby hamper priming and accumulation of tumor-infiltrating T-cells (44), indicating the importance of endogenous DCs for initiating antitumor immunity.”
Heterogeneity and fate choice: T cell exhaustion in cancer and chronic infections
Philip, M., & Schietinger, A. (2019) · Current Opinion in Immunology · doi:10.1016/j.coi.2019.04.014 · Cited by 120
Dai, P., Wang, W., Yang, N., Serna-Tamayo, C., Ricca, J. M., Zamarin, D., Shuman, S., Merghoub, T., Wolchok, J. D., & Deng, L. (2017) · Science Immunology · doi:10.1126/sciimmunol.aal1713 · Cited by 125
“(37) reported that the activation of oncogenic signaling pathway WNT/-catenin leads to the reduction of CD103+ DCs and antitumor T cells within the tumors.”
BackgroundMottini, C., Napolitano, F., Li, Z., Gao, X., & Cardone, L. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.023 · Cited by 118
Williford, J.-M., Ishihara, J., Ishihara, A., Mansurov, A., Hosseinchi, P., Marchell, T. M., Potin, L., Swartz, M. A., & Hubbell, J. A. (2019) · Science Advances · doi:10.1126/sciadv.aay1357 · Cited by 127
Immune-checkpoint inhibitor resistance in cancer treatment: Current progress and future directions
Zhang, C., Zhang, C., & Wang, H. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216182 · Cited by 128
Ji, L., Qian, W., Gui, L., Ji, Z., Yin, P., Lin, G. N., Wang, Y., Ma, B., & Gao, W. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3074 · Cited by 136
“However, we did not observe a decrease inCCL4 expression upon b-catenin activation in gastric cancer.”
BackgroundInfluentialSuryawanshi, A. S., Tadagavadi, R. K., Swafford, D., & Manicassamy, S. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00460 · Cited by 133
“Interestingly, recent study showed that melanoma-intrinsic β-catenin signaling suppresses antitumor immunity by regulating DC migration (74).”
BackgroundLazzari, C., Karachaliou, N., Bulotta, A., Viganó, M., Mirabile, A., Brioschi, E., Santarpia, M., Gianni, L., Rosell, R., & Gregorc, V. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918762094 · Cited by 117
Li, Z., Song, W., Rubinstein, M., & Liu, D. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0684-3 · Cited by 119
“The oncogenic pathways [50], such as PTEN loss [51, 52], and activation of the WNT/β-catenin signaling pathway [53] have been shown to lead to poor T cell infiltration and function in the tumor microenvironment.”
BackgroundOvercoming Chemotherapy Resistance in SCLC
Herzog, B. H., Devarakonda, S. H. K., & Govindan, R. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.07.018 · Cited by 132
Zhu, J., Ke, Y., Liu, Q., Yang, J. D., Liu, F., Xu, R., Zhou, H., Chen, A., Xiao, J., Meng, F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35130-7 · Cited by 130
Sharma, M. D., Rodriguez, P. C., Koehn, B. H., Baban, B., Cui, Y., Guo, G., Shimoda, M., Pacholczyk, R., Shi, H., Lee, E.-J., et al. (2018) · Immunity · doi:10.1016/j.immuni.2017.12.014 · Cited by 119
“While these conventional CD103+ DCs can be present in tumors, they are often limited in number, and many tumors appear to actively exclude them (Spranger et al., 2015).”
BackgroundSimonds, E. F., Lu, E. D., Badillo, O., Karimi, S., Liu, E. V., Tamaki, W., Rancan, C., Downey, K. M., Stultz, J., Sinha, M., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002181 · Cited by 119
Hypoxia and the phenomenon of immune exclusion
Pietrobon, V., & Marincola, F. M. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-020-02667-4 · Cited by 119
“A variety of non-inflamed tumors show WNT/β-catenin signaling pathway activation and in vivo experiments in melanomas proved that activation of the β-catenin signaling can dominantly exclude immune cell activation [276, 277].”
BackgroundRepurposing Drugs in Oncology (ReDO)—diclofenac as an anti-cancer agent
Pantziarka, P., Sukhatme, V., Bouche, G., Melhuis, L., & Sukhatme, V. P. (2016) · ecancermedicalscience · doi:10.3332/ecancer.2016.610 · Cited by 118
Genetic evolution of uveal melanoma guides the development of an inflammatory microenvironment
Gezgin, G., Doğrusöz, M., van Essen, T. H., Kroes, W. G. M., Luyten, G. P. M., van der Velden, P. A., Walter, V., Verdijk, R. M., van Hall, T., van der Burg, S. H., et al. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1991-1 · Cited by 119
Ganesh, S., Shui, X., Craig, K. P., Park, J., Wang, W., Brown, B. D., & Abrams, M. T. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.09.005 · Cited by 116
“Functionally, the modulation of b-catenin expression has been shown to have a large impact on tumor T cell content in preclinical models.(13) Similarly, oncogenic RAS signaling drives immunosuppression by increasing the stability of PD-L1 mRNA.”
BackgroundInfluentialRecent advances in the clinical development of immune checkpoint blockade therapy
Ghahremanloo, A., Soltani, A., Modaresi, S. M. S., & Hashemy, S. I. (2019) · Cellular Oncology · doi:10.1007/s13402-019-00456-w · Cited by 114
Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy
Pérez-Guijarro, E., Yang, H. H., Araya, R. E., El Meskini, R., Michael, H. T., Vodnala, S. K., Marie, K. L., Smith, C., Chin, S., Lam, K. C., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0818-3 · Cited by 118
Fu, C., Peng, P., Loschko, J., Li, F., Pham, P., Cui, W., Lee, K. P., Krug, A., & Jiang, A. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2002345117 · Cited by 122
Joung, J., Kirchgatterer, P. C., Singh, A., Cho, J. H., Nety, S. P., Larson, R. C., Macrae, R. K., Deasy, R., Tseng, Y., Maus, M. V., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29205-8 · Cited by 128
The Wnt signaling pathway: a potential therapeutic target against cancer
Ghosh, N., Hossain, U., Mandal, A., & Sil, P. C. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14027 · Cited by 123
Adoptive T cell therapy for solid tumors: current landscape and future challenges
Albarrán, V., Román, M. S., Pozas, J., Chamorro, J., Rosero, D. I., Guerrero, P., Calvo, J. C., González-Merino, C., de Quevedo, C. G., de Aguado, P. P., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1352805 · Cited by 128
Hope, C., Emmerich, P. B., Papadas, A., Pagenkopf, A., Matkowskyj, K. A., Van De Hey, D. R., Payne, S. N., Clipson, L., Callander, N. S., Hematti, P., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700529 · Cited by 111
“In particular, we confirm previous observations implicating melanoma-intrinsic WNT signaling in T cell exclusion and extend these findings to CRC (28).”
BackgroundResultFGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation
Yan, J., Zhao, Q., Gabrusiewicz, K. R., Kong, L.-Y., Xia, X., Wang, J., Ott, M., Xu, J., Davis, R. E., Huo, L., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08271-x · Cited by 122
DC-Derived Exosomes for Cancer Immunotherapy
Yao, Y., Fu, C., Zhou, L., Mi, Q., & Jiang, A. (2021) · Cancers · doi:10.3390/cancers13153667 · Cited by 121
Giles, J. R., Manne, S., Freilich, E., Oldridge, D. A., Baxter, A. E., George, S., Chen, Z., Huang, H., Chilukuri, L., Carberry, M., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.02.004 · Cited by 118
Cancer vaccines: current status and future directions
Zhou, Y., Wei, Y., Tian, X., & Wei, X. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01670-w · Cited by 133
Monitoring immune responses in the tumor microenvironment
Wargo, J. A., Reddy, S. M., Reuben, A., & Sharma, P. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.05.006 · Cited by 113
“Tissue DNA-based assays In addition to assessing immune markers within the microenvironment, there is increasing use of genomic profiling from tumor tissue and mounting evidence regarding the influence of genomic mutations on anti-tumor immunity [18,19 ,33].”
BackgroundGargett, T., Abbas, M. N., Rolan, P. E., Price, J. D., Gosling, K. M., Ferrante, A., Ruszkiewicz, A. R., Atmosukarto, I. I., Altin, J. G., Parish, C. R., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2207-z · Cited by 119
Cancer metastasis as a non-healing wound
Deyell, M., Garris, C. S., & Laughney, A. M. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01309-w · Cited by 113
“The activation of Wnt/β-catenin in tumour cells can also function in immune evasion by inhibiting the recruitment of CD103 dendritic cells, which are critical for adaptive immune recognition of the tumour.(14,129)”
BackgroundTurning tumors from cold to inflamed to improve immunotherapy response
Gerard, C. L., Delyon, J., Wicky, A. M., Homicskó, K., Cuendet, M. A., & Michielin, O. A. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102227 · Cited by 130
The complementarity of DDR, nucleic acids and anti-tumour immunity
Kornepati, A. V. R., Rogers, C. M., Sung, P., & Curiel, T. J. (2023) · Nature · doi:10.1038/s41586-023-06069-6 · Cited by 122
Exploiting lymphatic vessels for immunomodulation: Rationale, opportunities, and challenges
Maisel, K., Sasso, M. S., Potin, L., & Swartz, M. A. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.07.005 · Cited by 113
Controlling the Immune Suppressor: Transcription Factors and MicroRNAs Regulating CD73/NT5E
Kordaß, T., Osen, W., & Eichmüller, S. B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00813 · Cited by 122
3D models in the new era of immune oncology: focus on T cells, CAF and ECM
Modugno, F. D., Colosi, C., Trono, P., Antonacci, G., Ruocco, G., & Nisticò, P. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1086-2 · Cited by 121
“The paradigm of tumor intrinsic pathways related to T cell absence into the TME is represented by the WNT/ β-catenin pathway, which prevents the expression of C-C Motif Chemokine Ligand 4 (CCL4), a chemokine essential for DC and T cell recruitment [36].”
Muralidhar, S., Filia, A., Nsengimana, J., Poźniak, J., O'Shea, S. J., Diaz, J. M. S., Harland, M., Randerson‐Moor, J. A., Reichrath, J., Laye, J. P., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3927 · Cited by 121
Katoh, Y., Yaguchi, T., Kubo, A., Iwata, T., Morii, K., Kato, D., Ohta, S., Satomi, R., Yamamoto, Y., Oyamada, Y., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004616 · Cited by 124
“18 These results indicate that the SCD1/ β -catenin/ CCL4 pathway may also be involved in the non-T cell inflamed subtype of human colon cancer.”
BackgroundInfluentialWang, M. M., Coupland, S. E., Aittokallio, T. A., & Figueiredo, C. R. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02361-4 · Cited by 122
“T-cell exclusion WNT/β-catenin upregulation Anti‐CTLA-4, anti-PD-1/PD-L1 [42, 43, 46, 47]”
BackgroundMethodInfluentialTumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy
Mantuano, N. R., Natoli, M., Zippelius, A., & Laubli, H. P. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001222 · Cited by 127
Qi, Z., Xu, Z., Zhang, L., Zou, Y., Li, J., Yan, W., Li, C., Liu, N., & Wu, H. (2022) · Nature Communications · doi:10.1038/s41467-021-27833-0 · Cited by 137
Cancer cell-intrinsic mechanisms driving acquired immune tolerance
Ghorani, E., Swanton, C., & Quezada, S. A. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.004 · Cited by 125
“246 Studying transcriptional data from T cell inflamed vs. non-inflamed melanoma samples, Spranger et al. found Wnt/ b -catenin signaling to be upregulated in the latter, 247 a finding subsequently confirmed across cancer types.”
BackgroundCD8+ T cell-based cancer immunotherapy
Chen, Y., Yu, D., Qian, H., Shi, Y., & Tao, Z. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05134-6 · Cited by 130
“…signaling pathway has been proven a major route of tumor immunosuppression in colorectal cancer, breast cancer and melanoma [55]. β-catenin can promote the expression of transcription suppressor ATF3 to down-regulate CCL4, so to impede the recruitment of DCs and CD8 + T cells into tumors [56].”
BackgroundCancer stem cells and niches: challenges in immunotherapy resistance
Pan, Y., Yuan, C., Zeng, C., Sun, C., Xia, L., Wang, G., Chen, X., Zhang, B., Liu, J., & Ding, Z. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02265-2 · Cited by 122
“In melanoma, lung cancer, and colon cancer, activation of the Wnt/β-catenin signaling inhibits T cell infiltration and promotes tumor growth and therapeutic resistance by regulating the secretion of CCL4 and CCL5 [92, 93].”
Wnt/β-catenin signaling in melanoma: Preclinical rationale and novel therapeutic insights
Xue, G., Romano, E., Massi, D., & Mandalà, M. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.06.009 · Cited by 119
Mechanisms of Tumor Cell–Intrinsic Immune Evasion
Spranger, S., & Gajewski, T. F. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050606 · Cited by 108
“Activation of PI3K Through Loss of PTEN Loss-of-function mutation of PTEN is the second most frequent alteration associated with the non-T-cell-inflamed phenotype in metastatic melanoma (Peng et al. 2016, Spranger et al. 2015).”
BackgroundMethodSelf-citationDirecting Traffic: How to Effectively Drive T Cells into Tumors
Anandappa, A. J., Wu, C. J., & Ott, P. A. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0790 · Cited by 152
“This was first observed in patients with metastatic melanoma, with activation of the WNT/β-catenin pathway associated with an immune cold phenotype, and subsequently demonstrated to be correlated across tumor types in The Cancer Genome Atlas (25, 26).”
BackgroundWisdom, A. J., Mowery, Y. M., Hong, C. S., Himes, J. E., Nabet, B. Y., Qin, X., Zhang, D., Chen, L., Fradin, H., Patel, R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19917-0 · Cited by 120
Recent Advancements in Nanomedicine for ‘Cold’ Tumor Immunotherapy
Chen, Q., Sun, T., & Jiang, C. (2021) · Nano-Micro Letters · doi:10.1007/s40820-021-00622-6 · Cited by 124
Zhang, Y., Hou, X., Du, S., Xue, Y., Yan, J., Kang, D. D., Zhong, Y., Wang, C., Deng, B., McComb, D. W., et al. (2023) · Nature Nanotechnology · doi:10.1038/s41565-023-01453-9 · Cited by 122
Zhou, Y., Slone, N., Chrisikos, T. T., Kyrysyuk, O., Babcock, R. L., Medik, Y. B., Li, H. S., Kleinerman, E. S., & Watowich, S. S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000474 · Cited by 112
Mechanisms of Drug Resistance in Melanoma
Winder, M. L., & Virós, A. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_17 · Cited by 127
Wang, S., Wang, Y., Xun, X., Zhang, C., Xiao, X., Cheng, Q., Hu, S., Li, Z., & Zhu, J. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-1523-2 · Cited by 112
Towards a consensus definition of immune exclusion in cancer
Tiwari, A., Oravecz, T., Dillon, L. A. L., Italiano, A., Audoly, L., Fridman, W. H., & Clifton, G. T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1084887 · Cited by 129
Turning cold tumors into hot tumors to ignite immunotherapy
Liu, Y., Wang, Y., Wang, S., Li, J., He, W. A., Fan, X.-J., & Wan, X. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02477-6 · Cited by 135
Feng, M., Jin, J. Q., Xia, L., Xiao, T., Mei, S., Wang, X., Huang, X., Chen, J., Liu, M., Chen, C., et al. (2019) · Science Advances · doi:10.1126/sciadv.aau5240 · Cited by 117
“Our peptides could be applied to reset this disordered immune TME in CRC.”
BackgroundMethodInfluentialmRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients
Bidram, M., Zhao, Y., Shebardina, N. G., Baldin, A. V., Bazhin, A. V., Ganjalikhany, M. R., Zamyatnin, A. A., & Ganjalikhani-hakemi, M. (2021) · Vaccines · doi:10.3390/vaccines9101060 · Cited by 104
Oncogenic BRAFV600E Governs Regulatory T-cell Recruitment during Melanoma Tumorigenesis
Shabaneh, T. B., Molodtsov, A. K., Steinberg, S. M., Zhang, P., Torres, G. M., Mohamed, G. A., Boni, A., Curiel, T. J., Angeles, C. V., & Turk, M. J. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0365 · Cited by 103
Hedgehog Signaling in Lung Cancer: From Oncogenesis to Cancer Treatment Resistance
Leprieur, E. G., Costantini, A., Ding, V. W., & He, B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092835 · Cited by 123
Lepletier, A., Madore, J., O’Donnell, J. S., Johnston, R. L., Li, X.-Y., McDonald, E., Ahern, E. S., Kuchel, A., Eastgate, M. A., Pearson, S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3925 · Cited by 116
MYC: Master Regulator of Immune Privilege
Casey, S. C., Baylot, V., & Felsher, D. W. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.01.002 · Cited by 114
Katlinskaya, Y. V., Katlinski, K. V., Yu, Q., Ortiz, A., Beiting, D. P., Brice, A., Davar, D., Sanders, C., Kirkwood, J. M., Rui, H., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.006 · Cited by 108
“, 2015) and lacking in melanomas characterized by an activated β-catenin pathway (Spranger et al., 2015)) may affect overall expression of IFN ligands in the tumors.”
BackgroundBorodovsky, A., Barbon, C. M., Wang, Y., Ye, M., Prickett, L. B., Chandra, D., Shaw, J., Deng, N., Sachsenmeier, K. F., Clarke, J. D., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000417 · Cited by 116
T-cell-based immunotherapy in colorectal cancer
Feng, M., Zhao, Z., Yang, M., Ji, J., & Zhu, D. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.10.040 · Cited by 107
Wang, S., Xiong, Y., Zhang, Q., Su, D., Yu, C., Cao, Y., Pan, Y., Lu, Q., Zuo, Y., & Yang, L. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa311 · Cited by 140
Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy
Lu, B., Yang, M., & Wang, Q. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1397-0 · Cited by 112
Optogenetic Immunomodulation: Shedding Light on Antitumor Immunity
Tan, P., He, L., Han, G., & Zhou, Y. (2016) · Trends in biotechnology · doi:10.1016/j.tibtech.2016.09.002 · Cited by 113
“Oncogenic signals can not only suppress the intrinsic expression of chemokines to cause defective migration of dendritic cells (DCs) and impaired priming of cytotoxic T lymphocytes (CTLs) but also thwart DC differentiation and maturation or even switch anti-tumor DCs to “pro-tumor” DCs [2, 3].”
BackgroundInfluentialCalmeiro, J., Carrascal, M. A., Tavares, A. R., Ferreira, D. A., Gomes, C. M. F., Falcão, A. C., Cruz, M. T., & Neves, B. M. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020158 · Cited by 116
“In accordance with this, the activation of WNT/β-catenin in melanoma cells was shown to result in the ATF3-dependent repression of CCL4 transcription that in turn was correlated with decreased cDC1 numbers at the tumor site [94].”
BackgroundCutaneous melanoma and the immunotherapy revolution (Review)
Leonardi, G. C., Candido, S., Falzone, L., Spandidos, D. A., & Libra, M. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5088 · Cited by 123
“…is associated with a low IFN γ gene expression signature that can be mediated by activation of PTEN and WNT/ β -catenin pathway, impairment of JAK2 signaling or alteration of antigen presentation through structural or functional impairment of MHC class I mediated antigen presentation (100-103).”
Prognostic and predictive immune gene signatures in breast cancer
Bedognetti, D., Hendrickx, W., Marincola, F. M., & Miller, L. D. (2015) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000234 · Cited by 105
Molecular mechanisms involved in dendritic cell dysfunction in cancer
Tang, M., Diao, J., & Cattral, M. S. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2317-8 · Cited by 113
Solovyov, A., Vabret, N., Arora, K. S., Snyder, A., Funt, S. A., Bajorin, D. F., Rosenberg, J. E., Bhardwaj, N., Ting, D. T., & Greenbaum, B. D. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.042 · Cited by 102
“It was recently shown that active b-catenin signaling in metastatic melanoma samples results in T cell exclusion from the tumor microenvironment (Spranger et al., 2015).”
BackgroundImmunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges
Kunimasa, K., & Goto, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020597 · Cited by 110
Tang, Y., Durand, S., Dalle, S., & Caramel, J. (2020) · Cancers · doi:10.3390/cancers12082154 · Cited by 122
“Activation of the WNT/β-catenin pathway [81,82] or loss of PTEN expression [83] were also shown to promote T-cell exclusion and resistance to immunotherapy in melanoma.”
BackgroundRizzo, A., Ricci, A. D., Federico, A. D., Frega, G., Palloni, A., Tavolari, S., & Brandi, G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.803133 · Cited by 110
Intracellular complement C5a/C5aR1 stabilizes β-catenin to promote colorectal tumorigenesis
Ding, P., Xu, Y., Li, L., Lv, X., Li, L., Chen, J., Zhou, D., Wang, X., Wang, Q., Zhang, W., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110851 · Cited by 119
Dysregulated Wnt/β-catenin signaling confers resistance to cuproptosis in cancer cells
Liu, Y., Chen, L., Li, S., Wang, W., Wang, Y., Yang, Q., Song, A., Zhang, M.-J., Mo, W., Li, H., et al. (2024) · Cell Death and Differentiation · doi:10.1038/s41418-024-01341-2 · Cited by 126
“…stem cells from cuproptosis by regulating ATP7B. a Representative immunohistochemistry results show diminished TCF4 expression in normal mucosa (n = 42) in contrast to HNSCC tissues with different pathological grades (I, 53; II, 121; III, 36). b Kaplan – Meier analysis reveals worse overall…”
Convergent inducers and effectors of T cell paralysis in the tumour microenvironment
Hanahan, D., Michielin, O. A., & Pittet, M. J. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00761-z · Cited by 119
Srivastava, S., Jackson, C., Kim, T., Choi, J. H., & Lim, M. K. (2019) · Cancers · doi:10.3390/cancers11040537 · Cited by 113
Boyero, L., Sánchez-Gastaldo, A., Alonso, M. D., Noguera-Uclés, J. F., Molina‐Pinelo, S., & Bernabé, R. (2020) · Cancers · doi:10.3390/cancers12123729 · Cited by 112
“It has also been proposed that activation of the WNT/β-catenin signaling pathway in many tumors is involved in primary resistance to anti-PD-L1/anti-CTLA-4 monoclonal antibody therapy [133].”
BackgroundImmunotherapy Goes Local: The Central Role of Lymph Nodes in Driving Tumor Infiltration and Efficacy
van Pul, K. M., Fransen, M. F., van de Ven, R., & de Gruijl, T. D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.643291 · Cited by 107
“These observations were related to a decreased cDC1-related transcriptional signature in the tumor and an increased Wnt/β-catenin response signature, similar to observations previously reported by Spranger and colleagues in melanoma, showing that β-catenin-mediated restriction in cDC1 recruitment to the tumor stood in…”
ResultChung, H. K., McDonald, B., & Kaech, S. M. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20201730 · Cited by 108
ZEB1 transcription factor promotes immune escape in melanoma
Plaschka, M., Benboubker, V., Grimont, M., Berthet, J., Tonon, L., Lopez, J., Bouar, M. L., Balme, B., Tondeur, G., de la Fouchardière, A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003484 · Cited by 110
Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications
Giannone, G., Attademo, L., Scotto, G., Genta, S., Ghisoni, E., Tuninetti, V., Aglietta, M., Pignata, S., & Valabrega, G. (2019) · Cancers · doi:10.3390/cancers11111820 · Cited by 103
“This trial is one of several attempts to exploit immune microenvironment to target also CSCs on the basis of immune suppression induced by stem related pathways such as β-catenin in the Wnt signaling [129].”
BackgroundThe CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity
Ho, P., Melms, J. C., Rogava, M., Frangieh, C. J., Poźniak, J., Shah, S. B., Walsh, Z. H., Kyrysyuk, O., Amin, A. D., Caprio, L., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.05.014 · Cited by 118
Huang, L., Malu, S., McKenzie, J. A., Andrews, M. C., Talukder, A. H., Tieu, T., Karpinets, T., Haymaker, C., Forget, M.-A., Williams, L. J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2483 · Cited by 102
Targeting the Immune Microenvironment in the Treatment of Head and Neck Squamous Cell Carcinoma
Wang, H.-C., Chan, L.-P., & Cho, S.-F. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01084 · Cited by 99
“IDO1 converts tryptophan to kynurenine, which then activates aryl hydrocarbon receptor (AhR), a ligand-activated transcription factor, in Tregs, DCs, and NK cells.”
BackgroundInfluentialNon-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies
Santarpía, M., Aguilar, A., CHAIB-OUKADOUR, I., Cardona, A. F., Fancelli, S., Laguía, F., Bracht, J. W. P., Cao, P., Molina‐Vila, M. Á., Karachaliou, N., et al. (2020) · Cancers · doi:10.3390/cancers12061475 · Cited by 116
Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer
Mediratta, K., El‐Sahli, S., D’Costa, V. M., & Wang, L. (2020) · Cancers · doi:10.3390/cancers12123529 · Cited by 106
“Additionally, activation of β-catenin in tumor cells prevents spontaneous T-cell priming and infiltration of effector T-cells into the TME [136].”
BackgroundPromotion of growth factor signaling as a critical function of β-catenin during HCC progression
Kim, E., Lisby, A., Ma, C., Lo, N., Ehmer, U., Hayer, K. E., Furth, E. E., & Viatour, P. (2019) · Nature Communications · doi:10.1038/s41467-019-09780-z · Cited by 98
The Origin and Immune Recognition of Tumor-Specific Antigens
Apavaloaei, A., Hardy, M.-P., Thibault, P., & Perreault, C. (2020) · Cancers · doi:10.3390/cancers12092607 · Cited by 92
Tumor-infiltrating CD8+ T cell antitumor efficacy and exhaustion: molecular insights
Kumar, S., Singh, S. K., Rana, B., & Rana, A. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.01.002 · Cited by 118
“In human metastatic melanomas, upregulation of intrinsic WNT/β-catenin signaling is associated with the absence of a T cell gene signature [81].”
BackgroundKurebayashi, Y., Matsuda, K., Ueno, A., Tsujikawa, H., Yamazaki, K., Masugi, Y., Kwa, W. T., Effendi, K., Hasegawa, Y., Yagi, H., et al. (2021) · Hepatology · doi:10.1002/hep.32201 · Cited by 106
“Recent studies have shown that CTNNB1 mutation induces “immune- cold” microenvironment through suppressing the expression of CCL4 and CCL5[30,31] and it is also associated with VETC- positive HCC.”
BackgroundSridharan, V., Gjini, E., Liao, X., Chau, N. G., Haddad, R. I., Severgnini, M., Hammerman, P. S., El‐Naggar, A. K., Freeman, G. J., Hodi, F. S., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0031 · Cited by 102
Metadata
- Authors
- Spranger, S., Bao, R., & Gajewski, T. F.
- Affiliations
- University of Chicago (US)
- Corresponding author
- Gajewski, Thomas F.
- Venue
- Nature
- Published
- 2015-05-11
- Volume
- 523
- Issue
- 7559
- Pages
- 231-235
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1498931318
- Cited by
- 2,830
- References
- 45
- Citations by year
- 2026: 240 · 2025: 234 · 2024: 222 · 2023: 270 · 2022: 319 · 2021: 367 · 2020: 337 · 2019: 246 · 2018: 198 · 2017: 212 · 2016: 151 · 2015: 31
- FWCI
- 86.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- melanoma, β-catenin signaling, Wnt signaling, cancer immunotherapy resistance, PD-L1 blockade, CTLA-4 blockade, T-cell exclusion, tumor microenvironment, CD8+ T cell infiltration, tumor immune evasion, oncogenic signaling, immune checkpoint blockade
- MeSH terms
- Animals, Humans, Immunotherapy, Melanoma, T-Lymphocytes, Signal Transduction, Gene Expression Regulation, Neoplastic, Gene Expression Profiling, Wnt Proteins, beta Catenin, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.